| calcium channel, voltage-dependent, alpha2/delta subunit 1 |
BW-723C86 |
Calcium Channel Type L, Phenylalkylamine |
81% |
4.3383uM |
4.2178uM |
View
|
| epidermal growth factor receptor |
ZINC CHLORIDE |
Protein Tyrosine Kinase, EGF Receptor |
81% |
2.1884uM |
NoneNone |
View
|
| sodium channel, voltage-gated, type IV, beta |
CYCLIZINE |
Sodium Channel, Site 2 |
81% |
3.091uM |
2.82uM |
View
|
| sodium channel associated protein 1 |
CYCLIZINE |
Sodium Channel, Site 2 |
81% |
3.091uM |
2.82uM |
View
|
| sodium channel associated protein 2 |
CYCLIZINE |
Sodium Channel, Site 2 |
81% |
3.091uM |
2.82uM |
View
|
| sodium channel, voltage-gated, type III, beta |
CYCLIZINE |
Sodium Channel, Site 2 |
81% |
3.091uM |
2.82uM |
View
|
| sodium channel, voltage-gated, type I, alpha |
CYCLIZINE |
Sodium Channel, Site 2 |
81% |
3.091uM |
2.82uM |
View
|
| sodium channel, voltage-gated, type IX, alpha |
CYCLIZINE |
Sodium Channel, Site 2 |
81% |
3.091uM |
2.82uM |
View
|
| sodium channel, voltage-gated, type VII, alpha |
CYCLIZINE |
Sodium Channel, Site 2 |
81% |
3.091uM |
2.82uM |
View
|
| amiloride-sensitive cation channel 5, intestinal |
CYCLIZINE |
Sodium Channel, Site 2 |
81% |
3.091uM |
2.82uM |
View
|
| sodium channel, voltage-gated, type III, beta |
CYCLIZINE |
Sodium Channel, Site 2 |
81% |
3.091uM |
2.82uM |
View
|
| sodium channel, voltage-gated, type VIII, alpha polypeptide |
CYCLIZINE |
Sodium Channel, Site 2 |
81% |
3.091uM |
2.82uM |
View
|
| sodium channel, voltage-gated, type XI, alpha |
CYCLIZINE |
Sodium Channel, Site 2 |
81% |
3.091uM |
2.82uM |
View
|
| sodium channel, voltage-gated, type I, beta |
CYCLIZINE |
Sodium Channel, Site 2 |
81% |
3.091uM |
2.82uM |
View
|
| sodium channel, voltage-gated, type 10, alpha polypeptide |
CYCLIZINE |
Sodium Channel, Site 2 |
81% |
3.091uM |
2.82uM |
View
|
| sodium channel, voltage-gated, type IV, alpha polypeptide |
CYCLIZINE |
Sodium Channel, Site 2 |
81% |
3.091uM |
2.82uM |
View
|
| sodium channel, voltage-gated, type V, alpha polypeptide |
CYCLIZINE |
Sodium Channel, Site 2 |
81% |
3.091uM |
2.82uM |
View
|
| sodium channel, voltage-gated, type II, beta |
CYCLIZINE |
Sodium Channel, Site 2 |
81% |
3.091uM |
2.82uM |
View
|
| sodium channel, nonvoltage-gated 1 alpha |
CYCLIZINE |
Sodium Channel, Site 2 |
81% |
3.091uM |
2.82uM |
View
|
| sodium channel, nonvoltage-gated 1 gamma |
CYCLIZINE |
Sodium Channel, Site 2 |
81% |
3.091uM |
2.82uM |
View
|
| sodium channel, nonvoltage-gated 1 beta |
CYCLIZINE |
Sodium Channel, Site 2 |
81% |
3.091uM |
2.82uM |
View
|
| sodium channel, voltage-gated, type 2, alpha 1 polypeptide |
CYCLIZINE |
Sodium Channel, Site 2 |
81% |
3.091uM |
2.82uM |
View
|
| sodium channel, voltage-gated, type XI, alpha |
CYCLIZINE |
Sodium Channel, Site 2 |
81% |
3.091uM |
2.82uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1C subunit |
RESERPINE |
Calcium Channel Type L, Benzothiazepine |
79% |
3.707uM |
3.295uM |
View
|
| calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
RESERPINE |
Calcium Channel Type L, Benzothiazepine |
79% |
3.707uM |
3.295uM |
View
|
| calcium channel, voltage-dependent, beta 1 subunit |
RESERPINE |
Calcium Channel Type L, Benzothiazepine |
79% |
3.707uM |
3.295uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1E subunit |
RESERPINE |
Calcium Channel Type L, Benzothiazepine |
79% |
3.707uM |
3.295uM |
View
|
| calcium channel, voltage-dependent, N type, alpha 1B subunit |
RESERPINE |
Calcium Channel Type L, Benzothiazepine |
79% |
3.707uM |
3.295uM |
View
|
| calcium channel, voltage-dependent, alpha2/delta subunit 1 |
RESERPINE |
Calcium Channel Type L, Benzothiazepine |
79% |
3.707uM |
3.295uM |
View
|
| cholinergic receptor, muscarinic 4 |
OXYMETAZOLINE |
Muscarinic M4 |
79% |
3.261uM |
.455uM |
View
|
| Sigma-2 Receptor |
EBASTINE |
Sigma2 |
79% |
2.1858uM |
1.3451uM |
View
|
| mitogen activated protein kinase 3 |
CARMOFUR |
Protein Serine/Threonine Kinase, ERK1 |
79% |
6.121uM |
NoneNone |
View
|
| mitogen-activated protein kinase 3 |
CARMOFUR |
Protein Serine/Threonine Kinase, ERK1 |
79% |
6.121uM |
NoneNone |
View
|
| 5-hydroxytryptamine receptor 6 |
PROMETHAZINE |
Serotonin 5-HT6 |
79% |
2.429uM |
1.128uM |
View
|
| adrenergic receptor, alpha 2a |
PROMETHAZINE |
Imidazoline I2, Central |
79% |
1.988uM |
1.326uM |
View
|
| adrenergic receptor, alpha 2c (Non-specific probe) |
PROMETHAZINE |
Imidazoline I2, Central |
79% |
1.988uM |
1.326uM |
View
|
| adrenergic receptor, alpha 2b |
SIBUTRAMINE |
Adrenergic alpha2B |
79% |
2.39uM |
1.091uM |
View
|
| Cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase) |
SB-203580 |
CYP450-2C9 Inhibition |
79% |
1uM |
NoneNone |
View
|
| cytochrome P450, family 2, subfamily C, polypeptide 9 |
SB-203580 |
CYP450-2C9 Inhibition |
79% |
1uM |
NoneNone |
View
|
| tachykinin receptor 2 |
HALOPROGIN |
Tachykinin NK2 |
79% |
1.474uM |
.491uM |
View
|
| calcium channel, voltage-dependent, alpha2/delta subunit 1 |
FENOFIBRATE |
Calcium Channel Type L, Dihydropyridine |
79% |
17.672uM |
11.361uM |
View
|
| adrenergic receptor, alpha 1d (Non-specific probe) |
DIETHYLSTILBESTROL |
Adrenergic alpha1D |
79% |
10.826uM |
5.321uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2B |
DIETHYLSTILBESTROL |
Serotonin 5-HT2B |
79% |
3.14uM |
1.998uM |
View
|
| solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
MESTRANOL |
Adrenergic, Norepinephrine Transporter |
79% |
1.382uM |
1.371uM |
View
|
| adrenergic receptor, alpha 1d (Non-specific probe) |
HYDROXYCHLOROQUINE |
Adrenergic alpha1D |
79% |
4.772uM |
2.346uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 1A |
AMITRIPTYLINE |
Serotonin 5-HT1A |
79% |
1.996uM |
1.141uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 1B |
CHLORPROMAZINE |
Serotonin 5-HT1B |
79% |
4.041uM |
1.837uM |
View
|
| 5-hydroxytryptamine receptor 6 |
AMIODARONE |
Serotonin 5-HT6 |
79% |
19.441uM |
9.026uM |
View
|
| A3 adenosine receptor |
GOLD SODIUM THIOMALATE |
Adenosine A3 |
79% |
1.492uM |
.843uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 1A |
CLENBUTEROL |
Serotonin 5-HT1A |
79% |
2.652uM |
1.515uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 3a |
CLOZAPINE |
Serotonin 5-HT3 |
79% |
.866uM |
.195uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 3b |
CLOZAPINE |
Serotonin 5-HT3 |
79% |
.866uM |
.195uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 1A |
DEXFENFLURAMINE |
Serotonin 5-HT1A |
79% |
3.403uM |
1.944uM |
View
|
| dopamine receptor 2 |
BENZOTHIAZYL DISULFIDE |
Dopamine D2L |
79% |
5.866uM |
1.955uM |
View
|
| prostaglandin-endoperoxide synthase 1 |
CAFFEIC ACID PHENETHYL ESTER |
Cyclooxygenase COX-1 |
79% |
.833uM |
NoneNone |
View
|
| prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) |
CAFFEIC ACID PHENETHYL ESTER |
Cyclooxygenase COX-1 |
79% |
.833uM |
NoneNone |
View
|
| cholinergic receptor, nicotinic, alpha polypeptide 9 |
CARBACHOL |
Nicotinic Acetylcholine, Central |
79% |
1.003uM |
.334uM |
View
|
| cholinergic receptor, nicotinic, alpha polypeptide 10 |
CARBACHOL |
Nicotinic Acetylcholine, Central |
79% |
1.003uM |
.334uM |
View
|
| cholinergic receptor, nicotinic, epsilon polypeptide |
CARBACHOL |
Nicotinic Acetylcholine, Central |
79% |
1.003uM |
.334uM |
View
|
| cholinergic receptor, nicotinic, beta polypeptide 4 |
CARBACHOL |
Nicotinic Acetylcholine, Central |
79% |
1.003uM |
.334uM |
View
|
| cholinergic receptor, nicotinic, alpha polypeptide 5 |
CARBACHOL |
Nicotinic Acetylcholine, Central |
79% |
1.003uM |
.334uM |
View
|
| cholinergic receptor, nicotinic, beta polypeptide 1 (muscle) |
CARBACHOL |
Nicotinic Acetylcholine, Central |
79% |
1.003uM |
.334uM |
View
|
| histamine receptor H 2 |
DOXEPIN |
Histamine H2 |
79% |
1.867uM |
1.836uM |
View
|
| adrenergic receptor, beta 1 |
ISOPRENALINE |
Adrenergic beta1 |
79% |
.333uM |
.193uM |
View
|
| adrenergic, beta-1-, receptor |
ISOPRENALINE |
Adrenergic beta1 |
79% |
.333uM |
.193uM |
View
|
| solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
LABETALOL |
Dopamine Transporter |
79% |
1.607uM |
1.277uM |
View
|
| solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
ESTRIOL |
Serotonin Transporter |
79% |
10.336uM |
5.491uM |
View
|
| dopamine receptor D3 |
TRAZODONE |
Dopamine D3 |
79% |
3.743uM |
1.271uM |
View
|
| adenosine A2a receptor |
GENTIAN VIOLET |
Adenosine A2A |
79% |
3.365uM |
1.889uM |
View
|
| cholinergic receptor, muscarinic 2 |
EPERISONE |
Muscarinic M2 |
79% |
2.338uM |
.831uM |
View
|
| androgen receptor |
BROMOCRIPTINE |
Testosterone |
79% |
2.281uM |
1.521uM |
View
|
| adrenergic receptor, alpha 1b |
VERAPAMIL |
Adrenergic alpha1B |
79% |
1.698uM |
.94uM |
View
|
| histamine receptor H 2 |
VERAPAMIL |
Histamine H2 |
79% |
2.59uM |
2.547uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 8 |
FELODIPINE |
Calcium Channel Type L, Benzothiazepine |
79% |
.023uM |
.02uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 7 |
FELODIPINE |
Calcium Channel Type L, Benzothiazepine |
79% |
.023uM |
.02uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 6 |
FELODIPINE |
Calcium Channel Type L, Benzothiazepine |
79% |
.023uM |
.02uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 6 |
FLUPHENAZINE |
Calcium Channel Type L, Benzothiazepine |
82% |
8.618uM |
7.66uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 5 |
FLUPHENAZINE |
Calcium Channel Type L, Benzothiazepine |
82% |
8.618uM |
7.66uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 4 |
FLUPHENAZINE |
Calcium Channel Type L, Benzothiazepine |
82% |
8.618uM |
7.66uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 3 |
FLUPHENAZINE |
Calcium Channel Type L, Benzothiazepine |
82% |
8.618uM |
7.66uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 2 |
FLUPHENAZINE |
Calcium Channel Type L, Benzothiazepine |
82% |
8.618uM |
7.66uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 1 |
FLUPHENAZINE |
Calcium Channel Type L, Benzothiazepine |
82% |
8.618uM |
7.66uM |
View
|
| calcium channel, voltage-dependent, beta 4 subunit |
FLUPHENAZINE |
Calcium Channel Type L, Benzothiazepine |
82% |
8.618uM |
7.66uM |
View
|
| calcium channel, voltage-dependent, beta 3 subunit |
FLUPHENAZINE |
Calcium Channel Type L, Benzothiazepine |
82% |
8.618uM |
7.66uM |
View
|
| calcium channel, voltage-dependent, beta 2 subunit |
FLUPHENAZINE |
Calcium Channel Type L, Benzothiazepine |
82% |
8.618uM |
7.66uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1S subunit |
FLUPHENAZINE |
Calcium Channel Type L, Benzothiazepine |
82% |
8.618uM |
7.66uM |
View
|
| calcium channel, voltage-dependent, alpha 1F subunit |
FLUPHENAZINE |
Calcium Channel Type L, Benzothiazepine |
82% |
8.618uM |
7.66uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1D subunit |
FLUPHENAZINE |
Calcium Channel Type L, Benzothiazepine |
82% |
8.618uM |
7.66uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1C subunit |
FLUPHENAZINE |
Calcium Channel Type L, Benzothiazepine |
82% |
8.618uM |
7.66uM |
View
|
| calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
FLUPHENAZINE |
Calcium Channel Type L, Benzothiazepine |
82% |
8.618uM |
7.66uM |
View
|
| calcium channel, voltage-dependent, beta 1 subunit |
FLUPHENAZINE |
Calcium Channel Type L, Benzothiazepine |
82% |
8.618uM |
7.66uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1E subunit |
FLUPHENAZINE |
Calcium Channel Type L, Benzothiazepine |
82% |
8.618uM |
7.66uM |
View
|
| calcium channel, voltage-dependent, N type, alpha 1B subunit |
FLUPHENAZINE |
Calcium Channel Type L, Benzothiazepine |
82% |
8.618uM |
7.66uM |
View
|
| calcium channel, voltage-dependent, alpha2/delta subunit 1 |
FLUPHENAZINE |
Calcium Channel Type L, Benzothiazepine |
82% |
8.618uM |
7.66uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 1A |
DOXEPIN |
Serotonin 5-HT1A |
82% |
1.519uM |
.868uM |
View
|
| mitogen activated protein kinase 1 |
SULINDAC SULFIDE |
Protein Serine/Threonine Kinase, ERK2 |
82% |
1.092uM |
NoneNone |
View
|
| mitogen-activated protein kinase 1 |
SULINDAC SULFIDE |
Protein Serine/Threonine Kinase, ERK2 |
82% |
1.092uM |
NoneNone |
View
|
| melanocortin 5 receptor |
CISPLATIN |
Melanocortin MC5 |
82% |
6.434uM |
6.035uM |
View
|
| epidermal growth factor receptor |
CISPLATIN |
Protein Tyrosine Kinase, EGF Receptor |
82% |
2.621uM |
NoneNone |
View
|
| solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
MIANSERIN |
Serotonin Transporter |
82% |
2.068uM |
1.098uM |
View
|
| opioid receptor, kappa 1 |
LOPERAMIDE |
Opiate kappa |
82% |
3.125uM |
1.25uM |
View
|
| cholinergic receptor, muscarinic 3 |
KETOTIFEN |
Muscarinic M3 |
82% |
2.209uM |
.468uM |
View
|
| mu-opioid receptor MOR |
SAQUINAVIR |
Opiate mu |
82% |
9.625uM |
3.907uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 8 |
BOPINDOLOL |
Calcium Channel Type L, Phenylalkylamine |
82% |
2.904uM |
2.824uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 7 |
BOPINDOLOL |
Calcium Channel Type L, Phenylalkylamine |
82% |
2.904uM |
2.824uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 6 |
BOPINDOLOL |
Calcium Channel Type L, Phenylalkylamine |
82% |
2.904uM |
2.824uM |
View
|
| sodium channel, voltage-gated, type II, alpha 2 |
GUANABENZ |
Sodium Channel, Site 2 |
82% |
3.591uM |
3.276uM |
View
|
| sodium channel, voltage-gated, type I, beta |
GUANABENZ |
Sodium Channel, Site 2 |
82% |
3.591uM |
3.276uM |
View
|
| sodium channel, voltage-gated, type I, alpha |
GUANABENZ |
Sodium Channel, Site 2 |
82% |
3.591uM |
3.276uM |
View
|
| sodium channel, voltage-gated, type IV, beta |
GUANABENZ |
Sodium Channel, Site 2 |
82% |
3.591uM |
3.276uM |
View
|
| Sigma-2 Receptor |
PIPAMAZINE |
Sigma2 |
82% |
.604uM |
.372uM |
View
|
| adrenergic receptor, alpha 1d (Non-specific probe) |
MICONAZOLE |
Adrenergic alpha1D |
82% |
3.046uM |
1.497uM |
View
|
| solute carrier family 28 (sodium-coupled nucleoside transporter), member 1 |
KETOCONAZOLE |
Adenosine Transporter |
82% |
4.412uM |
1.51uM |
View
|
| adenine nucleotide translocase (DBSS) (Non-specific probe) |
KETOCONAZOLE |
Adenosine Transporter |
82% |
4.412uM |
1.51uM |
View
|
| solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 4 |
KETOCONAZOLE |
Adenosine Transporter |
82% |
4.412uM |
1.51uM |
View
|
| solute carrier family 28 (sodium-coupled nucleoside transporter), member 3 |
KETOCONAZOLE |
Adenosine Transporter |
82% |
4.412uM |
1.51uM |
View
|
| concentrative Na+ nucleoside cotransporter (DBSS) |
KETOCONAZOLE |
Adenosine Transporter |
82% |
4.412uM |
1.51uM |
View
|
| Sigma-2 Receptor |
LEFLUNOMIDE |
Sigma2 |
45% |
NoneNone |
NoneNone |
View
|
| synaptic vesicle glycoprotein 2b |
BENZO[A]PYRENE |
beta-Lactamase |
82% |
20.682uM |
NoneNone |
View
|
| calcium channel, voltage-dependent, L type, alpha 1D subunit |
DEXCHLORPHENIRAMINE |
Calcium Channel Type L, Phenylalkylamine |
82% |
3.805uM |
3.699uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1C subunit |
DEXCHLORPHENIRAMINE |
Calcium Channel Type L, Phenylalkylamine |
82% |
3.805uM |
3.699uM |
View
|
| calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
DEXCHLORPHENIRAMINE |
Calcium Channel Type L, Phenylalkylamine |
82% |
3.805uM |
3.699uM |
View
|
| calcium channel, voltage-dependent, beta 1 subunit |
DEXCHLORPHENIRAMINE |
Calcium Channel Type L, Phenylalkylamine |
82% |
3.805uM |
3.699uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1E subunit |
DEXCHLORPHENIRAMINE |
Calcium Channel Type L, Phenylalkylamine |
82% |
3.805uM |
3.699uM |
View
|
| sodium channel, nonvoltage-gated 1, gamma |
CYCLIZINE |
Sodium Channel, Site 2 |
81% |
3.091uM |
2.82uM |
View
|
| sodium channel, nonvoltage-gated 1, delta |
CYCLIZINE |
Sodium Channel, Site 2 |
81% |
3.091uM |
2.82uM |
View
|
| sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) |
CYCLIZINE |
Sodium Channel, Site 2 |
81% |
3.091uM |
2.82uM |
View
|
| sodium channel, nonvoltage-gated 1 alpha |
CYCLIZINE |
Sodium Channel, Site 2 |
81% |
3.091uM |
2.82uM |
View
|
| sodium channel, voltage-gated, type X, alpha |
CYCLIZINE |
Sodium Channel, Site 2 |
81% |
3.091uM |
2.82uM |
View
|
| sodium channel, voltage-gated, type IX, alpha |
CYCLIZINE |
Sodium Channel, Site 2 |
81% |
3.091uM |
2.82uM |
View
|
| sodium channel, voltage gated, type VIII, alpha |
CYCLIZINE |
Sodium Channel, Site 2 |
81% |
3.091uM |
2.82uM |
View
|
| sodium channel, voltage-gated, type VII, alpha |
CYCLIZINE |
Sodium Channel, Site 2 |
81% |
3.091uM |
2.82uM |
View
|
| sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) |
CYCLIZINE |
Sodium Channel, Site 2 |
81% |
3.091uM |
2.82uM |
View
|
| sodium channel, voltage-gated, type IV, beta |
CYCLIZINE |
Sodium Channel, Site 2 |
81% |
3.091uM |
2.82uM |
View
|
| sodium channel, voltage-gated, type IV, alpha |
CYCLIZINE |
Sodium Channel, Site 2 |
81% |
3.091uM |
2.82uM |
View
|
| sodium channel, voltage-gated, type III, alpha |
CYCLIZINE |
Sodium Channel, Site 2 |
81% |
3.091uM |
2.82uM |
View
|
| calcium channel, voltage-dependent, beta 4 subunit |
ORPHENADRINE |
Calcium Channel Type L, Benzothiazepine |
80% |
2.232uM |
1.984uM |
View
|
| calcium channel, voltage-dependent, beta 3 subunit |
ORPHENADRINE |
Calcium Channel Type L, Benzothiazepine |
80% |
2.232uM |
1.984uM |
View
|
| calcium channel, voltage-dependent, beta 2 subunit |
ORPHENADRINE |
Calcium Channel Type L, Benzothiazepine |
80% |
2.232uM |
1.984uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1S subunit |
ORPHENADRINE |
Calcium Channel Type L, Benzothiazepine |
80% |
2.232uM |
1.984uM |
View
|
| calcium channel, voltage-dependent, alpha 1F subunit |
ORPHENADRINE |
Calcium Channel Type L, Benzothiazepine |
80% |
2.232uM |
1.984uM |
View
|
| dopamine receptor 2 |
PROMETHAZINE |
Dopamine D2L |
80% |
.779uM |
.26uM |
View
|
| thromboxane A synthase 1 |
LACIDIPINE |
Thromboxane Synthetase |
80% |
1.694uM |
NoneNone |
View
|
| thromboxane A synthase 1 (platelet, cytochrome P450, family 5, subfamily A) |
LACIDIPINE |
Thromboxane Synthetase |
80% |
1.694uM |
NoneNone |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2C |
DAPIPRAZOLE |
Serotonin 5-HT2C |
80% |
.625uM |
.327uM |
View
|
| acetylcholinesterase (YT blood group) |
BENZETHONIUM CHLORIDE |
Acetylcholinesterase |
80% |
2.246uM |
NoneNone |
View
|
| collagen-like tail subunit (single strand of homotrimer) of asymmetric acetylcholinesterase |
BENZETHONIUM CHLORIDE |
Acetylcholinesterase |
80% |
2.246uM |
NoneNone |
View
|
| acetylcholinesterase |
BENZETHONIUM CHLORIDE |
Acetylcholinesterase |
80% |
2.246uM |
NoneNone |
View
|
| melanocortin 5 receptor |
ASTEMIZOLE |
Melanocortin MC5 |
80% |
2.263uM |
2.123uM |
View
|
| Cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase) |
FINASTERIDE |
CYP450-2C9 Inhibition |
80% |
2uM |
NoneNone |
View
|
| cytochrome P450, family 2, subfamily C, polypeptide 9 |
FINASTERIDE |
CYP450-2C9 Inhibition |
80% |
2uM |
NoneNone |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2A |
HALOPROGIN |
Serotonin 5-HT2A |
80% |
2.421uM |
.692uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2A |
DIPHENHYDRAMINE |
Serotonin 5-HT2A |
80% |
1.295uM |
.37uM |
View
|
| cholinergic receptor, muscarinic 5 |
DROPERIDOL |
Muscarinic M5 |
80% |
2.298uM |
1.651uM |
View
|
| adenosine A2a receptor |
TRIOXSALEN |
Adenosine A2A |
80% |
1.312uM |
.737uM |
View
|
| sodium channel, voltage-gated, type III, beta |
TRIHEXYPHENIDYL |
Sodium Channel, Site 2 |
80% |
2.797uM |
2.552uM |
View
|
| sodium channel, voltage-gated, type VIII, alpha polypeptide |
TRIHEXYPHENIDYL |
Sodium Channel, Site 2 |
80% |
2.797uM |
2.552uM |
View
|
| sodium channel, voltage-gated, type XI, alpha |
TRIHEXYPHENIDYL |
Sodium Channel, Site 2 |
80% |
2.797uM |
2.552uM |
View
|
| sodium channel, voltage-gated, type I, beta |
TRIHEXYPHENIDYL |
Sodium Channel, Site 2 |
80% |
2.797uM |
2.552uM |
View
|
| sodium channel, voltage-gated, type 10, alpha polypeptide |
TRIHEXYPHENIDYL |
Sodium Channel, Site 2 |
80% |
2.797uM |
2.552uM |
View
|
| sodium channel, voltage-gated, type IV, alpha polypeptide |
TRIHEXYPHENIDYL |
Sodium Channel, Site 2 |
80% |
2.797uM |
2.552uM |
View
|
| sodium channel, voltage-gated, type V, alpha polypeptide |
TRIHEXYPHENIDYL |
Sodium Channel, Site 2 |
80% |
2.797uM |
2.552uM |
View
|
| sodium channel, voltage-gated, type II, beta |
TRIHEXYPHENIDYL |
Sodium Channel, Site 2 |
80% |
2.797uM |
2.552uM |
View
|
| sodium channel, nonvoltage-gated 1 alpha |
TRIHEXYPHENIDYL |
Sodium Channel, Site 2 |
80% |
2.797uM |
2.552uM |
View
|
| sodium channel, nonvoltage-gated 1 gamma |
TRIHEXYPHENIDYL |
Sodium Channel, Site 2 |
80% |
2.797uM |
2.552uM |
View
|
| sodium channel, nonvoltage-gated 1 beta |
TRIHEXYPHENIDYL |
Sodium Channel, Site 2 |
80% |
2.797uM |
2.552uM |
View
|
| sodium channel, voltage-gated, type 2, alpha 1 polypeptide |
TRIHEXYPHENIDYL |
Sodium Channel, Site 2 |
80% |
2.797uM |
2.552uM |
View
|
| sodium channel, voltage-gated, type XI, alpha |
TRIHEXYPHENIDYL |
Sodium Channel, Site 2 |
80% |
2.797uM |
2.552uM |
View
|
| sodium channel, nonvoltage-gated 1, gamma |
TRIHEXYPHENIDYL |
Sodium Channel, Site 2 |
80% |
2.797uM |
2.552uM |
View
|
| sodium channel, nonvoltage-gated 1, delta |
TRIHEXYPHENIDYL |
Sodium Channel, Site 2 |
80% |
2.797uM |
2.552uM |
View
|
| sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) |
TRIHEXYPHENIDYL |
Sodium Channel, Site 2 |
80% |
2.797uM |
2.552uM |
View
|
| sodium channel, nonvoltage-gated 1 alpha |
TRIHEXYPHENIDYL |
Sodium Channel, Site 2 |
80% |
2.797uM |
2.552uM |
View
|
| sodium channel, voltage-gated, type X, alpha |
TRIHEXYPHENIDYL |
Sodium Channel, Site 2 |
80% |
2.797uM |
2.552uM |
View
|
| sodium channel, voltage-gated, type IX, alpha |
TRIHEXYPHENIDYL |
Sodium Channel, Site 2 |
80% |
2.797uM |
2.552uM |
View
|
| sodium channel, voltage gated, type VIII, alpha |
TRIHEXYPHENIDYL |
Sodium Channel, Site 2 |
80% |
2.797uM |
2.552uM |
View
|
| sodium channel, voltage-gated, type VII, alpha |
TRIHEXYPHENIDYL |
Sodium Channel, Site 2 |
80% |
2.797uM |
2.552uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 5 |
FELODIPINE |
Calcium Channel Type L, Benzothiazepine |
79% |
.023uM |
.02uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 4 |
FELODIPINE |
Calcium Channel Type L, Benzothiazepine |
79% |
.023uM |
.02uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 3 |
FELODIPINE |
Calcium Channel Type L, Benzothiazepine |
79% |
.023uM |
.02uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 2 |
FELODIPINE |
Calcium Channel Type L, Benzothiazepine |
79% |
.023uM |
.02uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 1 |
FELODIPINE |
Calcium Channel Type L, Benzothiazepine |
79% |
.023uM |
.02uM |
View
|
| calcium channel, voltage-dependent, beta 4 subunit |
FELODIPINE |
Calcium Channel Type L, Benzothiazepine |
79% |
.023uM |
.02uM |
View
|
| calcium channel, voltage-dependent, beta 3 subunit |
FELODIPINE |
Calcium Channel Type L, Benzothiazepine |
79% |
.023uM |
.02uM |
View
|
| calcium channel, voltage-dependent, beta 2 subunit |
FELODIPINE |
Calcium Channel Type L, Benzothiazepine |
79% |
.023uM |
.02uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1S subunit |
FELODIPINE |
Calcium Channel Type L, Benzothiazepine |
79% |
.023uM |
.02uM |
View
|
| calcium channel, voltage-dependent, alpha 1F subunit |
FELODIPINE |
Calcium Channel Type L, Benzothiazepine |
79% |
.023uM |
.02uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1D subunit |
FELODIPINE |
Calcium Channel Type L, Benzothiazepine |
79% |
.023uM |
.02uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1C subunit |
FELODIPINE |
Calcium Channel Type L, Benzothiazepine |
79% |
.023uM |
.02uM |
View
|
| calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
FELODIPINE |
Calcium Channel Type L, Benzothiazepine |
79% |
.023uM |
.02uM |
View
|
| calcium channel, voltage-dependent, beta 1 subunit |
FELODIPINE |
Calcium Channel Type L, Benzothiazepine |
79% |
.023uM |
.02uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1E subunit |
FELODIPINE |
Calcium Channel Type L, Benzothiazepine |
79% |
.023uM |
.02uM |
View
|
| calcium channel, voltage-dependent, N type, alpha 1B subunit |
FELODIPINE |
Calcium Channel Type L, Benzothiazepine |
79% |
.023uM |
.02uM |
View
|
| calcium channel, voltage-dependent, alpha2/delta subunit 1 |
FELODIPINE |
Calcium Channel Type L, Benzothiazepine |
79% |
.023uM |
.02uM |
View
|
| adrenergic receptor, alpha 2b |
METHYSERGIDE |
Adrenergic alpha2B |
79% |
4.763uM |
2.175uM |
View
|
| v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
ZIRCONIUM(IV) CHLORIDE |
Protein Tyrosine Kinase, HER2 Receptor |
79% |
1.163uM |
NoneNone |
View
|
| v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
ZIRCONIUM(IV) CHLORIDE |
Protein Tyrosine Kinase, HER2 Receptor |
79% |
1.163uM |
NoneNone |
View
|
| mitogen activated protein kinase 14 |
4-(PHENYLMETHYL)-1-[2-(TRIFLUOROMETHYL)BENZOYL]-PIPERIDINE |
Protein Serine/Threonine Kinase, p38alpha |
79% |
.715uM |
NoneNone |
View
|
| mitogen-activated protein kinase 14 |
4-(PHENYLMETHYL)-1-[2-(TRIFLUOROMETHYL)BENZOYL]-PIPERIDINE |
Protein Serine/Threonine Kinase, p38alpha |
79% |
.715uM |
NoneNone |
View
|
| adrenergic receptor, beta 2 |
CLORPRENALINE |
Adrenergic beta2 |
79% |
1.993uM |
1.37uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 8 |
RESERPINE |
Calcium Channel Type L, Benzothiazepine |
79% |
3.707uM |
3.295uM |
View
|
